News
Asda car parks to provide alternative locations for breast cancer screening in England
The initiative is hoped to contribute towards wider efforts to increase visibility and awareness of the importance of breast screening
Asda’s car parks in specific regions of the country will be used by NHS England to increase convenience and visibility of vital breast screening services and encourage more women to come forward for their mammogram.
This comes at the same time as the UK leading breast cancer charity, Breast Cancer Now, steps up its campaigning efforts to improve breast screening uptake, following years of declining screening attendance.
The announcement was made as part of an Asda parliamentary event, hosted by Matt Vickers MP, which focussed on supporting community organisations, utilising store space and fundraising for national charities.
Asda is currently hosting three mobile breast screening vans in England, as well as one in Scotland.
The retailer says it looks forward to working with regional commissioning teams across England to identify further locations where mobile breast screening vans could make a difference.
This initiative is hoped to contribute towards wider efforts to increase visibility and awareness of the importance of breast screening and encourage more women to take up their breast screening invite.
“We’re delighted that NHS England and our long-term partner, Asda, are working together to improve the convenience of vital breast screening, with ASDA offering many of their car parks as locations for breast screening vans in England,” said Baroness Delyth Morgan, chief executive at Breast Cancer Now.
“Breast screening is a key tool for detecting breast cancer early, as critically, the sooner the disease is diagnosed, the more likely treatment is to be successful.
“As such, we welcome this important initiative which will help improve people’s awareness of breast screening and could provide this vital service in new areas of the community.”
Dr Nisha Sharma, director of breast screening and clinical lead for breast imaging at Leeds Teaching Hospital NHS Trust, said: “Breast Screening is a vital tool in detecting cancers at an earlier stage, which can make all the difference, and we’re so pleased to have this local breast screening mobile unit in Morley Asda car park available, providing a convenient and accessible option to so many women.”
Jo Warner, senior director corporate responsibility and ESG/Asda spokesperson, said: “With breast screening attendance declining in recent years, we knew we could do something practical to help.
“Opening up space in our car parks to host mobile screening units felt like a natural extension to three decades of fundraising and breast cancer awareness raising efforts and our hope is it will help to improve visibility and convenience of screening and ultimately drive earlier diagnosis and better outcomes for those affected by breast cancer.”
Jeanette Lane, who works on the kiosk at Asda Dagenham, knows all too well how important it is to attend routine breast screening.
Following her mammogram in March 2018, the results found invasive breast cancer in one breast and non-invasive breast cancer in the other breast. Following numerous biopsies, it was confirmed she had invasive lobular breast cancer.
Jeanette then had biopsies on her lymph nodes in July, and in August 2018. She had a double mastectomy with immediate first stages of reconstruction, followed by radiotherapy. She then went on to have full reconstruction surgery in 2019.
“The one thing I would say to everyone is to keep checking yourself regularly, and don’t miss any routine mammograms,” she said.
“If I hadn’t attended my mammogram appointment, I would never have known about my breast cancer.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Hormonal health2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Entrepreneur4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







11 Comments